AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05428488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept (W12-W48)
Description: The experimental strategy will evaluate abatacept 125 mg/week following 12 weeks of anti-TNF prescribed in usual care. Concomitant treatment with stable doses of csDMARD, non-steroidal anti-inflammatory drugs, analgesic agents, glucocorticoids (≤10 mg of prednisone or the equivalent per day), or a combination of these drugs will be permitted.~Patients will continue to take methotrexate or leflunomide for the duration of the study.
Study NCT05428488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF Inhibitor (W12-W48)
Description: In the control group, the 88 randomized RA patients will be treated with TNF inhibitor subcutaneous for 36 weeks. In case of insufficient response to a first TNF inhibitor at 24 or 36 weeks, a second TNF inhibitor will be proposed.
Study NCT05428488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF Inhibitor (W0-W12)
Description: All included patients will receive TNF inhibitors subcutaneous for 12 weeks.
Study NCT05428488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF Inhibitor (W0-W12)
Description: All included patients will receive TNF inhibitors subcutaneous for 12 weeks.
Study NCT06302894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-sufficiency
Description: Rewarding positive behavior and developing alternative behaviors towards obstacles such as feeling restless, depressed or angry if internet use is reduced or controlled.
Study NCT05240560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP1.3656
Description: Histamine H3 receptor antagonist/inverse agonist
Study NCT05240560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BP1.3656
Description: Histamine H3 receptor antagonist/inverse agonist
Study NCT04860791 — intervention group
Intervention type: OTHER
Intervention: questionnaires
Description: Patients will complete the MSWDQ-23 in French, as well as the DEX, questionnaire for the evaluation of executive dysfunction in daily life, to evaluate their cognitive complaints and the SF36 questionnaire to evaluate their quality of life
Study NCT05828472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: MY008211A tablets, low/moderate/high dose orally, for 7 days
Study NCT05828472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets matched placebo
Description: MY008211A tablets matched placebo, low/moderate/high dose orally, for 7 days
Study NCT04732611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Pilates group participants will perform 3 weekly Pilates sessions lasting approximately 50 minutes for 20 weeks.
Study NCT04765579 — intervention group
Intervention type: BEHAVIORAL
Intervention: visual analogy scala
Description: We will investigate the effect of 4in1 block by questioning the vas score of the patients, its effect on quadriceps strength, and additional analgesia needs for 24 hours.
Study NCT06250985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of reimplantation
Description: Patients will be rendomized 1:1 by computer to recieve either standart care or intervention prior to removal of infected system
Study NCT06250985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of reimplantation
Description: Patients will be rendomized 1:1 by computer to recieve either standart care or intervention prior to removal of infected system
Study NCT06088030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Patients should be treated with the corresponding first-line chemotherapy regimen first, for example: Neuroblastoma: CAV (cyclophosphamide, pinarubicin, vincristine), PVP (cisplatin, etoposide) ,CT (cyclophosphamide, topotecan).If patients was evaluted as PD/SD after treatments, arsenic trioxide (ATO) will be administered 0.18mg/kg per day over six hours IV daily for ten days in combination with previous chemotherapy regimen on the third day of each treatment cycle. Other pediatric tumors with TP53 mutations not mentioned above will have similar treatment regimens. If the efficacy of the conventional standard chemotherapy regimen is evaluated as PD/SD, then the next course of treatment will be combined with ATO on the basis of the standard chemotherapy regimen.
Study NCT05115487 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: digital dynamometer
Description: Hand grip strength will be measured using a hand-held digital dynamometer with the patient sitting in a hard chair and elbow flexed to 90°. All assessments and measurements will be made by the same experienced physician blinded to patients' clinical data.
Study NCT04927104 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK Knee Prosthesis
Description: After subjects drop out of the study for any reason, the researchers can perform revision surgery using the prosthetic joint that is now routinely used.
Study NCT06385717 — intervention group
Intervention type: RADIATION
Intervention: chemo-radiation
Description: different Chemo-radiotherapy regimen
Study NCT06126367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombotic assessment
Description: The Global Thrombosis Test (Thromboquest Limited, UK) is an in vitro method imitating high shear stress conditions akin to that which exist in a severely stenosed artery. The test measures platelet reactivity (occlusion time) and endogenous fibrinolysis time (lysis time).~Thromboelastography is a technique that assesses the whole process of clotting and its viscoelastic properties, from the initial activation and aggregation of platelets, to the role of thrombin and finally the stability of the formed clot, as a measure of fibrinolytic resistance.~Plasma will be stored for subsequent analysis of other thrombotic, fibrinolytic, inflammatory and coagulation markers as deemed appropriate.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification.
Study NCT06126367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of Lp(a)
Description: Lp(a) will be measured by particle enhanced immunotubidimetricassay. Human lipoprotein (a) agglutinates with latex particles coated with anti-Lp(a) antibodies. The precipitate is determined turbidimetrically at 800 / 660 nm. The platform employed will be the Roche® Immunoassay Analyser (Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim). Traceability: This method has been standardized against the IFCC (International Federation of Clinical Chemistry) reference material SRM2B for nmol/L.~For patients deemed eligible for treatment with either a PCSK9i or inclisiran, this will be assessed prior to commencing treatment and also 3-6 months after starting treatment.~This will only be assessed once for patients with moderate or severe aortic valve calcification.
Study NCT04732611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking protocol
Description: Walking group participants will perform 3 weekly walking sessions lasting approximately 50 minutes for 20 weeks.
Study NCT05484817 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of cardiovascular risk factor, endocrine hormones and related biomarker
Description: Cardiovascular risk factors: glycated hemoglobin/C-peptide/continuous glucose monitoring/blood pressure, blood lipids, uric acid, microalbumin test, etc. Endocrin hormones: bone metabolism, sex hormones, adrenal and pituitary hormones, and related biomarkers
Study NCT05648149 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hierarchical multi-dimensional cognitive training scheme based on computer
Description: The scheme was constructed five main categories of cognitive function: (1) attention, memory, numeracy, thinking response and perception; (2) There are 10 training items, which are drawing, quick matching, flash memory, number memory, face memory, color tracking, number span, word naming, symbol number form, quick arithmetic; (3) Each training item is divided into basic and advanced training. Only if the basic training reaches more than 80%, can the advanced training be entered; (4) In order to facilitate patient training, all items were embedded in the wechat mini program, and corresponding cognitive training was carried out in the mini program; (5)Small program background can monitor training results.
Study NCT05577364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Selinexor: 40mg qw po, and 60mg qw po (phase Ib); RP2D (II study);~Selinexor is added from the second cycle of R-CHOP regimen.
Study NCT05577364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP Protocol
Description: Rituximab: 375mg/m2 iv.drip D1;~Cyclophosphamide: 750mg/m2 iv.drip D1;~Doxorubicin: 50mg/m2 iv.drip D1;~Vincristine: 1.4g/m2 iv D1;~Prednisone: 100mg po D1-5;
Study NCT04770259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timely pre-surgical conditioning
Description: Timely pre-surgical conditioning seeks to prepare frail, pre-frail and / or dependent older patients for the surgery process. For which a work plan has been designed according to your needs and health conditions.
Study NCT06202313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Participants receive Cadonilimab 10mg/kg IV on Day 1 of each 21-day cycle PLUS Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
Study NCT06202313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Participants receive Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
Study NCT06202313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Participants receive Eribulin 1.4mg/m\^2 IV on Days 1 and 8 of each 21-day cycle.
Study NCT05819268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ReACT
Description: ReACT includes 12 sessions with a therapist that will discuss a plan for managing FS.
Study NCT05819268 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CATCH-IT
Description: CATCH-IT involves the parent and child completing CBT modules on the web-based CATCH-IT platform, and they will meet with a CATCH-IT coach 12 times to discuss the modules and plan how to apply this to their life and their FS.
Study NCT04665921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-STNV
Description: Given into the vein (IV; intravenously)
Study NCT06633978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediTrain
Description: Participants will engage with a digital meditation app for 30m/day for 6wks. MediTrain is a tablet-based, meditation-inspired, cognitive training game aimed at improving self-regulation of internal attention and distractions. It was developed in collaboration with meditation thought-leader Jack Kornfield, and Zynga, a world-class video game company. It was created to make benefits of concentrative meditation more easily accessible to anyone, including complete novices. This is achieved by creating a game that yields quantifiable and attainable goals, provides feedback, and includes an adaptive algorithm to gradually increase difficulty as users improve.
Study NCT06633978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wrist worn multi-sensor watches
Description: Stress and sleep data will be recorded at home throughout the intervention using FDA-approved wrist worn multi-sensor watches.
Study NCT04787198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic saline
Description: The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of hypertonic saline (7% NaCl) will be administered to the FDI muscle using a 1 mL syringe with a disposable needle (27G), and 30 the volume of the bolus will be 0.2 mL .
Study NCT04787198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: The site of injections will be determined by palpation of the contracted First Dorsal Interosseus (FDI) muscle. The skin will be cleaned with alcohol before injection. A bolus injection of 0.2 mL isotonic saline (9 mg/mL) will be administered to the FDI muscle as control.
Study NCT06633978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep monitor
Description: Sleep Profiler devices are FDA-cleared reduced-montage EEG recording devices that will be used in accordance with its FDA clearance. They are completely non-invasive and are designed to be comfortable enough to wear all night without interfering with normal sleep. These devices enable quality sleep recordings in the comfort of people's homes, rather than required an overnight stay at a sleep lab at UCSF.
Study NCT05254457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Treatment or retreatment with up to two doses of EN3835
Study NCT06421402 — intervention group
Intervention type: OTHER
Intervention: Air quality monitoring at patient's home
Description: Indoor Air Quality:~- MICA-INBIOT system: temperature (ºC), humidity (%), CO2 (ppm), total Volatile Organic Ccompounds (VOCs) (ppb), Formaldehyde (µg/m3); and Particulate Matter (PM) 1/2.5/4/10 (µg/m3)~Outdoor Air Quality:~- Aeris Weather platform: NO, NO2, NOx, SO2, SO3, CO, and PM10, all expressed in µg/m3
Study NCT06421402 — intervention group
Intervention type: OTHER
Intervention: Questionnaires: Baseline & every six months
Description: General surveys:~* PROMs: ICHOM Adult Set; encompassing Patient Reported Outcomes Measurement Information System (PROMIS 10), World Health Organization Wellbeing Index (WHO 5) and World Health Organization Disability Assessment Schedule (WHO-DAS 12) questionnaires.~* PREMs: Patient-Reported Indicator Survey (PaRIS)~Disease specific questionaires:~* COPD: COPD Assessment Test (CAT); modified Medical Research Council (mMRC) Dyspnea scale.~* Asthma: Asthma Control Test (ACT); Test of Adherence to Inhalers (TAI-12); Asthma Quality of Life Questionnaire (mini AQLQ); Sino-Nasal Outcome Test (SNOT-22).
Study NCT06421402 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function Testing: Baseline & every six months & during exacerbations
Description: * Forced Spirometry: Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1)~* Forced Oscillation Technique: Impedance, resistance and reactance.~Ancillary measurements: Systemic arterial pressure and pulse oximetry.
Study NCT06421402 — intervention group
Intervention type: OTHER
Intervention: EMR & registry data
Description: Electronic Medical Records (EMRs): Updated every twelve months to track clinical events from Hospital and Primary Care databases.~Registry data: from the Catalan Health Surveillance System (CHSS).
Study NCT06421402 — intervention group
Intervention type: DEVICE
Intervention: Communication channel - Health Circuit Mobile App (Herranz C. JMIR 2023)
Description: Health Circuit: chat, short questionnaires (Likert scale). As needed.
Study NCT06421402 — intervention group
Intervention type: DEVICE
Intervention: Physiological data - Beat One Watch
Description: Enhanced with real-time physiological data tracking (heart rate, steps walked and Heart Rate Variability (HRV))
Study NCT06421402 — intervention group
Intervention type: DEVICE
Intervention: Patient Empowerment
Description: Mobile App Health Circuit: follow-up of the personalized action plan agreed with the patient \& reference doctor
Study NCT05488873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST-057 Active
Description: WST-057 Topical Solution
Study NCT05488873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo Topical Solution
Study NCT06421402 — intervention group
Intervention type: OTHER
Intervention: Characteristics of exacerbations
Description: Health Circuit: home-based oscillometry, daily disease-specific questionnaire during the acute episode and continuous assessment of physiological variables.
Study NCT05185895 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 15 minutes eccentric cycling
Description: The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
Study NCT05185895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15 minutes eccentric cycling
Description: The exposure to eccentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
Study NCT05185895 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 15 minutes concentric (normal) cycling
Description: The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
Study NCT05185895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15 minutes concentric (normal) cycling
Description: The exposure to concentric exercise will be individualized-intensity stepwise incremental cycle exercise starting at 50 Watt with individually tailored increments every 5 minutes.
Study NCT04643119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medial Congruent Insert
Description: The Medial Congruent Bearing (MC Bearing) design was introduced in 2016 for use with the Zimmer-Persona Cruciate-Retaining Femur: the design facilitates greater stability through increased anterior lip height compared to the original Cruciate Retaining Bearing (CR Bearing), allowing for greater anterior constraint and subluxation resistance that aids in full extension and deep flexion. Furthermore, the MC Bearing has been suggested for use in patients presenting with more complicated surgical histories (e.g prior high tibial osteotomies or patellectomies), whereas the original CR Bearing is strictly suggested for use only in patients undergoing knee surgery for the first time, where the posterior cruciate ligament may still be intact.
Study NCT04643119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cruciate-Retaining Insert
Description: The Cruciate-Retaining Bearing (CR Bearing) design was launched together with the use of the Cruciate-Retaining Femoral Components (CR Femur) of the Zimmer-Biomet Persona® Total Knee system. The design not only stabilises the knee through medial conformity and anterior constraint, but also allows for freer and more natural deep flexion through freer movement of the lateral condyle.
Study NCT05531721 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation and retrospective data collection
Study NCT05394480 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood pressure (Systolic, Diastolic), Pulse value, O2 saturations were measured.
Description: Salivary cortisol was measured by electrochemiluminescence (ECLIA) method using the Cobas Cortisol ll kit.
Study NCT05079399 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Blood samples will be collected via venipuncture
Study NCT05841199 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure and flow measurement during simulated VT
Description: Participants undergoing coronary angiography will have measurements of blood pressure, coronary pressure and coronary flow during simulated VT. VT will be simulated using pacing at a range of heart rates.
Study NCT05823012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levothyroxine sodium
Description: Levothyroxine sodium 10 mg/mL
Study NCT06021626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD3874
Description: Starting dose is 0.1 mg/kg for weekly IV infusion of CRD3874-SI.~Cohort CRD3874-SI Dose level (mg/kg)~1. 0.1~2. 0.3~3. 0.9~4. 1.8~5. 2.7~6. 4.05
Study NCT06633094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational videos
Description: Internet will be used to deliver educational videos to subjects enrolled in the home management arm of the study which will be available on the Carilion Clinic Orthopaedic Education YouTube Channel. This will consist of a prerecorded video made by the three pediatric orthopaedic surgeons on this study explaining the nature of buckle fractures and treatment. Participants will be sent a link to the video over email (an example of a similar video in clinical use at Carilion Orthopaedics and the script of the video can be found in the study document attached).
Study NCT05972330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VRx MyBiotics Oral Lozenges
Description: VRx MyBiotics Oral Lozenges are composed of prebiotics, probiotics, and postbiotics.
Study NCT05705076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: catheter induced thromboprophylaxis
Description: Direct oral anticoagulation for catheter induced thromboprophylaxis
Study NCT05705076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: catheter induced thromboprophylaxis
Description: Direct oral anticoagulation for catheter induced thromboprophylaxis
Study NCT05102227 — intervention group
Intervention type: DEVICE
Intervention: Left bundle branch area pacing
Description: A dual-chamber DF-1 defibrillator is implanted. Left bundle branch area pacing is performed for cardiac resynchronization therapy.
Study NCT06470178 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: corhot1: chemotherapy combined with fruquintinib
Description: Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles.
Study NCT06470178 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: corhot2: chemotherapy combined with fruquintinib
Description: Chemotherapy Drugs: Selection based on clinical guidelines/indications and patient condition.For example, recommended chemotherapy regimens: mFOLFOX6 or CAPEOX.~Fruquintinib: 3mg (starting dose), PO (once daily). Dosing schedule and dosage can be adjusted based on concurrent chemotherapy and immune checkpoint inhibitors. Have received fruquintinib treatment for at least 2 cycles.